These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 8365360)
21. A segment of five amino acids in the second extracellular loop of the cholecystokinin-B receptor is essential for selectivity of the peptide agonist gastrin. Silvente-Poirot S; Wank SA J Biol Chem; 1996 Jun; 271(25):14698-706. PubMed ID: 8663021 [TBL] [Abstract][Full Text] [Related]
22. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179. Silvente Poirot S; Hadjiivanova C; Escrieut C; Dufresne M; Martinez J; Vaysse N; Fourmy D Eur J Biochem; 1993 Mar; 212(2):529-38. PubMed ID: 8444190 [TBL] [Abstract][Full Text] [Related]
23. Exogenous CCK and gastrin stimulate pancreatic exocrine secretion via CCK-A but also via CCK-B/gastrin receptors in the calf. Le Dréan G; Le Huërou-Luron I; Gestin M; Desbois C; Romé V; Bernard C; Dufresne M; Moroder L; Gully D; Chayvialle JA; Fourmy D; Guilloteau P Pflugers Arch; 1999 Jun; 438(1):86-93. PubMed ID: 10370091 [TBL] [Abstract][Full Text] [Related]
24. Analysis of the carbohydrate composition of the pancreatic plasmalemmal glycoprotein affinity labeled by short probes for the cholecystokinin receptor. Pearson RK; Miller LJ; Hadac EM; Powers SP J Biol Chem; 1987 Oct; 262(28):13850-6. PubMed ID: 3654639 [TBL] [Abstract][Full Text] [Related]
25. Nucleoside diphosphate kinase associated with rat pancreatic membranes regulates CCK receptor affinity. Blevins GT; van de Westerlo EM; Williams JA Am J Physiol; 1994 Nov; 267(5 Pt 1):G866-74. PubMed ID: 7977749 [TBL] [Abstract][Full Text] [Related]
27. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors. Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778 [TBL] [Abstract][Full Text] [Related]
28. Pancreatic secretory response to feeding in the calf: CCK-A receptors, but not CCK-B/gastrin receptors are involved. Le Dréan G; Le Huërou-Luron I; Gestin M; Romé V; Bernard C; Chayvialle JA; Fourmy D; Guilloteau P Can J Physiol Pharmacol; 2000 Oct; 78(10):813-9. PubMed ID: 11077982 [TBL] [Abstract][Full Text] [Related]
29. High affinity binding of cholecystokinin to small cell lung cancer cells. Yoder DG; Moody TW Peptides; 1987; 8(1):103-7. PubMed ID: 3033616 [TBL] [Abstract][Full Text] [Related]
30. Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas. Bell RH; Kuhlmann ET; Jensen RT; Longnecker DS Cancer Res; 1992 Jun; 52(12):3295-9. PubMed ID: 1596887 [TBL] [Abstract][Full Text] [Related]
31. The biochemical characterization of the native pancreatic cholecystokinin receptor using affinity labeling approaches. Miller LJ Yale J Biol Med; 1992; 65(5):441-8; discussion 465-9. PubMed ID: 1340061 [TBL] [Abstract][Full Text] [Related]
32. Both CCK-A and CCK-B/gastrin receptors are present on rabbit vagus nerve. Lin CW; Miller TR Am J Physiol; 1992 Sep; 263(3 Pt 2):R591-5. PubMed ID: 1415646 [TBL] [Abstract][Full Text] [Related]
33. Use of the heterobifunctional cross-linker m-maleimidobenzoyl N-hydroxysuccinimide ester to affinity label cholecystokinin binding proteins on rat pancreatic plasma membranes. Madison LD; Rosenzweig SA; Jamieson JD J Biol Chem; 1984 Dec; 259(23):14818-23. PubMed ID: 6094576 [TBL] [Abstract][Full Text] [Related]
34. A reduced pancreatic protein secretion in response to cholecystokinin (CCK) in the obese Zucker rat correlates with a reduced receptor capacity for CCK. Praissman M; Izzo RS Endocrinology; 1986 Aug; 119(2):546-53. PubMed ID: 3015550 [TBL] [Abstract][Full Text] [Related]
35. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353 [TBL] [Abstract][Full Text] [Related]
36. Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: utilization of a novel Xenopus laevis cholecystokinin receptor. Schmitz F; Pratt DS; Wu MJ; Kolakowski LF; Beinborn M; Kopin AS Mol Pharmacol; 1996 Aug; 50(2):436-41. PubMed ID: 8700154 [TBL] [Abstract][Full Text] [Related]
37. Functional cholecystokinin receptors are distinguished kinetically by biotinyl-Tyr-Gly-(Thr28,Nle31)CCK(25-33) in rat pancreatic acini. Winand J; Poloczek P; Delporte C; Moroder L; Svoboda M; Christophe J Biochim Biophys Acta; 1991 Oct; 1080(2):181-90. PubMed ID: 1718434 [TBL] [Abstract][Full Text] [Related]
38. Heterogeneity of cholecystokinin receptors in pancreas. Madison LD; Jamieson JD; Rosenzweig SA Biochem Biophys Res Commun; 1987 Mar; 143(2):761-7. PubMed ID: 3105532 [TBL] [Abstract][Full Text] [Related]
39. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Reubi JC; Schaer JC; Waser B Cancer Res; 1997 Apr; 57(7):1377-86. PubMed ID: 9102227 [TBL] [Abstract][Full Text] [Related]
40. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]